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Available online 28 December 2018AbstractPurpose: To evaluate the outcome of trabeculectomy versus Ahmed glaucoma valve (AGV) surgery in patients with Fuchs uveitis Syndrome
(FUS).
Methods: Twenty-eight eyes with uncontrolled glaucoma and at least 6 months of follow-up were enrolled. In 16 eyes trabeculectomy and in 12
eyes AGV implant were performed. The primary outcome measure was surgical success defined as 5 < intraocular pressure (IOP)  21 mmHg
(criterion A) and 5 < IOP  16 mmHg (criterion B), with at least 20% reduction in IOP, either with no medication (complete success) or with no
more than preoperative medications (qualified success). The sum of complete and qualified success was defined as cumulative success.
Results: The mean age of the patients in the trabeculectomy group and the AGV group was 44.92 ± 9.02 and 45.76 ± 7.10 years, respectively
(P ¼ 0.79). The mean duration of follow-up was 23.06 ± 12.03 months in the trabeculectomy group and 22.83 ± 13.63 months in the AGV group
(P ¼ 0.96). The baseline mean IOP in trabeculectomy was 26.81 ± 6.69 mmHg which decreased to 11.61 ± 4.15 mmHg at last visit (P < 0.001).
In the AGV group, mean IOP was 31.41 ± 6.76 at baseline that changed to 22.41 ± 5.09 at last visit (P ¼ 0.005). According to criterion A,
cumulative success rates were 100% and 91% at 6 months and 76% and 9% at 36 months in the trabeculectomy and the AGV group,
respectively. Cumulative success rates at 6 months were 93% and 58% and 65% and 7% at 36 months according to criterion B in the trabe-
culectomy and the AGV group, respectively.
Kaplan-Meier survival analysis revealed a significant association between surgical method and cumulative success rate over 36 months
(based on criteria A: P ¼ 0.02, and based on criteria B: P ¼ 0.007).
Conclusion: The success rate of trabeculectomy was higher than AGV in the surgical management of glaucoma in FUS during a medium-term
follow-up.
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Fuchs uveitis syndrome (FUS) or Fuchs heterochromic iri-
docyclitis (FHI) is a low-grade, chronic intraocular inflamma-
tory disease which accounts for 1.5%e4.5% of all uveitis.1,2
Most patients with FUS are diagnosed on routine ophthal-
mological examination in their third or fourth decade of life,
without gender preference.3e6 FUS usually affects one eye,
causing iris heterochromia without ocular discomfort or
pain.7e10osting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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however, because of the favorable results of cataract surgery,
glaucoma is considered the most serious complication.11,12
The intraocular pressure (IOP) elevation in these patients is
often intermittent and sub-acute in the early stages and may
respond to the short-term use of topical corticosteroids.13
Several possible causes have been proposed for the rise of
IOP such as recurrent hyphema, neovascularization of the
angle, peripheral anterior synechiae, trabeculitis, trabecular
sclerosis, the collapse of the Schlemm's canal, corticosteroid
treatment, and cataract extraction, but usually, no single and
apparent reason can be found.5,8,14e16 Few studies have
explained the management of glaucoma in FUS and reported
that medical management was not a sufficient
treatment.13,17e19 For uveitic patients with uncontrolled
glaucoma, several procedures have been performed, such as
trabeculectomy, glaucoma drainage implants, ciliary body
destructive procedures, and angle surgeries.20e23 However,
little information is available in the literature about the sur-
gical outcome of glaucoma in FUS patients.24e26
In this study, we aimed to compare the outcome of two
different types of glaucoma surgery, trabeculectomy and
Ahmed glaucoma valve (AGV), in patients with FUS.
Methods
In this retrospective cohort study, we reviewed the charts of
all FUS patients with secondary glaucoma who underwent
glaucoma surgery from 2010 to 2015. The study design was
approved by the Ethics Committee of the Iran University of
Medical Sciences, and all patients signed the inform consent.
Twenty-eight eyes of 28 patients with at least 6 months of
follow-up who met the inclusion criteria were enrolled in this
study. Inclusion criteria were patients with FUS that required
glaucoma surgery due to the insufficiency of medical treat-
ment to achieve the target IOP or low compliance of patients
for medical therapy. Exclusion criterion was previous intra-
ocular surgeries except history of uncomplicated cataract
surgery more than 6 months before glaucoma surgery and any
other ocular diseases that could influence the results, such as
history or presence of diabetic retinopathy or retinal vascular
diseases. FUS diagnosis was according to the clinical features
described by Kimura et al., in 1955 and La Hey et al. in 1991,
which included: characteristic diffusely spread stellate shape
keratic precipitates (KPs), low-grade anterior chamber reac-
tion, iris atrophy and depigmentation with or without hetero-
chromia, absence of posterior synechiae, open angle in
gonioscopy and lack of acute symptoms of severe pain,
redness, and photophobia during follow-up visits.5,26 Glau-
coma was defined as the presence of glaucomatous optic
neuropathy (neuroretinal rim loss, vertical cup: disc ratio
0.7, asymmetric cup: disc ratio >0.2 between two eyes and
nerve fiber loss in the fundoscopic examination) and corre-
sponding glaucomatous visual field defect.27 Demographic
data and preoperative findings such as best corrected visual
acuity (BCVA), IOP (measured by calibrated Goldmann
applanation tonometry), slit-lamp biomicroscopy fundoscopy(using 78 diopter lens), gonioscopy, number of glaucoma
medications, mean deviation in Humphrey visual field test as
well as corresponding postoperative values at each follow-up
visit were collected. Betamethasone eye drop, 4 times a day,
was started from 7 days before the date of the surgery for all
patients.
Since there was no strong evidence regarding the better
outcome of either of these surgeries in comparison to other
one, patients were allocated to each group according to the
socioeconomic condition, compliance for the possible strict
postoperative visits, and preference of the patients based on
the information given by the surgeon about the possibility of
complications and reoperation following each surgery.
The primary outcome measure was defined as the surgical
success based on two criteria: 5 < IOP  21 mmHg (criterion
A) and 5 < IOP  16 mmHg (criterion B) with at least 20%
reduction in IOP either with no medication (complete success)
or no more than preoperative medications (qualified success).
Cumulative success was defined as the sum of qualified and
complete success. Subjects with IOP outside the range of suc-
cess on 2 consecutive visits after month 3 or those who needed
repeated glaucoma surgery were classified as a failure. Needling
of the bleb behind the slit-lamp was not considered a failure.Surgical techniqueSurgeries were performed under local or general anesthesia
by a single surgeon (N.N.) by considering the age or systemic
condition of the patient. In the trabeculectomy group, each
patient underwent a fornix-based trabeculectomy by making a
conjunctival flap in the supranasal quadrant followed by a half
thickness trapezoidal scleral flap (3  2 mm). After creating
the scleral flap, mitomycin C (MMC) 0.02% was applied using
multiple thin sponges under the scleral flap and between the
sclera and tenon capsule for 3 min. The sponges then were
removed, and the surgical field was irrigated with copious
amounts of balanced salt solution. Sclerectomy was performed
with a Kelly-Descemet punch, and a peripheral iridectomy
was created with Vannas scissors. The scleral flap was secured
with two 10-0 nylon sutures using the releasable technique. At
the end of the surgery, the conjunctiva was closed with 10-
0 nylon sutures, and subtenon long-acting betamethasone was
injected in the inferotemporal quadrant.
In the shunt group, fornix-based peritomy was performed in
the superotemporal quadrant, and MMC 0.02% was applied
for 2 min and then irrigated with 50 CC balanced salt solution.
After priming of AGV model FP7 (New World Medical,
Rancho Cucamonga, LA) with a balanced salt solution, it was
secured to the sclera with two 8-0 nylon sutures 10e11 mm
behind the limbus. The tube was trimmed beveled up and then
inserted into the anterior chamber through the tunnel made by
a 23 gauge needle at the posterior limbus. The tube was then
secured to the sclera with a 10-0 nylon suture and covered with
a donor sclera. Conjunctiva was closed with 10 vicryl suture in
a continuous fashion. At the end of the surgery subtenon, long-
acting betamethasone was injected in the inferotemporal
quadrant.
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floxacin eye drops every 6 h for approximately 1e2 weeks and
betamethasone eye drops every 2 h for approximately 2 weeks
which was tapered gradually to 2 times a day over the next
8e12 weeks and then was switched to fluorometholone twice
a day for the next 1e2 months. Patients were examined on
postoperative day 1 and then at least weekly for 4 weeks and
then every 1e3 months based on the clinical judgment. IOP
lowering medication was started after the surgery according to
the stages of glaucoma, target IOP, and discretion of the
surgeon.
Serious intraoperative complications were defined as supra
choroidal hemorrhage, vitreous loss, vitreous hemorrhage,
malignant glaucoma, and scleral flap tear or dehiscence.
Postoperative complications were defined as extensive or
kissing choroidal detachment, malignant glaucoma, supra-
choroidal hemorrhage, retinal vascular accident, blebitis, or
endophthalmitis.
The hypertensive phase (HP) was defined as IOP mea-
surement >21 mmHg during the first 3 months after AGV
surgery (with or without medications), after reduction of IOP
to less than 21 mmHg during the first postoperative week, and
not as a result of tube obstruction, retraction, or valve
malfunctions.28Statistical analysisData analysis was performed using SPSS software version
16 (SPSS for Windows, Chicago, IL). Data were reported as
mean ± SD and frequency (relative frequency). Chi-square
and student T-test were used to compare proportion and
means, respectively. The cumulative probability of success
was analyzed by KaplaneMeier life table analysis. P-value of
<0.05 was considered significant.
Results
A total of 28 eyes with the diagnosis of FUS and glaucoma
with no history of previous glaucoma surgery were enrolled in
the study. Sixteen patients (53.5%) were in the trabeculectomy
group, and 12 patients (46.5%) were in the shunt group. EightTable 1
Baseline characteristics of patients with Fuchs uveitis Syndrome (FUS) treated wi
Trabecule
Age, year (mean ± SD) 44.92 ± 9
Number of cases (male) 16 (8)
Preoperative IOP (mean ± SD) mmHg (range)
95% confidence interval (lower-upper)
26.81 ± 6
(23.50e2
Preoperative number of anti-glaucoma medications (mean ± SD),
(range)




Preoperative visual acuity (mean ± SD) logMAR 0.4 ± 0.3
Preoperative mean deviation in visual field (mean ± SD) Decibel 10.40 ±
Lens status phakic/pseudophakic 4/12
IOP: Intraocular pressure.patients (46.6%) in the trabeculectomy and 7 patients
(58.30%) in the AGV group were men. Table 1 shows the
baseline characteristics of the patients in trabeculectomy and
shunt groups. All cases with pseudophakia had a previous
history of uncomplicated temporal clear cornea phaco surgery.
The conjunctiva was completely intact at the superior part in
these cases.
Mean ± SD of the follow-up period was 23.06 ± 12.03
(range, 6e36) and 22.83 ± 13.63 months (range, 6e36) in the
trabeculectomy and AGV group, respectively (P ¼ 0.96).
At last visit, IOP was significantly lower compared with
baseline IOP in both groups, but the number of medication
was lowered only in the trabeculectomy group compared with
baseline (Table 2). Fig. 1A,B show the mean IOP and number
of medications during the follow-up period in each group. The
IOP changes between baseline, 6 months, one year, and last
visit values were not significantly different between the two
groups (All P > 0.05). The mean percent of IOP changes in the
6th month, and 1 year from baseline values were not signifi-
cantly different between the two groups (P > 0.05), but it was
significantly higher in the trabeculectomy group at last visit
(P ¼ 0.02).
Complete success was achieved in 75% and 50% of tra-
beculectomy cases based on criterion A and B, respectively. In
the AGV group, all cases received medication, thus, complete
success was not achieved in this group.
Table 3 shows the cumulative success rate during the
follow-up period in two groups based on two criteria. Overall,
the failure occurred in 7 (43.75%) patients of the AGV group
and 2 (16.66%) patients of the trabeculectomy group based on
criterion A, and in 10 (62.5%) patients of the AGV group and
4 (33.33%) patients of the trabeculectomy group based on
criterion B.
Kaplan-Meier analysis revealed a significant association
between surgical method and total success rate over 36 months
(based on criteria A: P ¼ 0.02, and based on criteria B:
P ¼ 0.007) in favor of trabeculectomy (Fig. 2A, B).
In the AGV group, the HP was detected in 4 patients (30%).
In both groups, there were no serious intraoperative or post-
operative complications. In the AGV group, one eye had
postoperative hyphema, and in the trabeculectomy group, twoth trabeculectomy and Ahmed glaucoma valve (AGV).
ctomy Ahmed glaucoma valve (AGV) Independent t-test
and Chi-square Test
.02 45.76 ± 7.1 P ¼ 0.79
12 (7) P ¼ 0.54
.69 (18e38)
7.75)









0.4 ± 0.26 P ¼ 1.00
15.42 13.97 ± 11.23 P ¼ 0.43
3/9 P ¼ 0.83
Fig. 1. A: Pre-operation and Post-operation intraocular pressure (IOP) measures in two surgical groups. B: Pre-operation and post-operation number of medications
in two surgical groups.
Table 2
Comparison of intraocular pressure (IOP) and number of anti-glaucoma medication between baseline and last postoperative visits in each group.
Type of surgery Variable Baseline visit Last visit P value
Trabeculectomy IOP mmHg (mean ± SD) 26.81 ± 6.69 (18e38) 12.31 ± 4.98 <0.001
(range) (23.50e27.75) (521)
95% confidence interval (lower-upper) (9.93e14.68)
Anti-glaucoma 2.62 ± 0.80 0.68 ± 1.19 <0.001
Medication (mean ± SD)
(range) (1e4) (0e3)
95% confidence interval (lower-upper) (2.18e3.00) (0.18e1.33)
Ahmed glaucoma valve (AGV) IOP mmHg (mean ± SD) 31.41 ± 6.76 21.83 ± 7.05 0.002
(range) (22e40) (13e40)
95% confidence interval (lower-upper) (27.60e35.33) (18.25e26.33)
Anti-glaucoma medication (mean ± SD) 3.00 ± 0.95 (1e4) 2.16 ± 0.93 0.010
(range) (1e4) (1e4)
95% confidence interval (lower-upper) (2.5e3.5) (1.66e2.66)
IOP: Intraocular pressure.
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Fig. 2. A: Comparison of the cumulative success rate of Ahmed glaucoma valve (AGV) surgery and trabeculectomy based on criterion A in patients with Fuchs
uveitis Syndrome (FUS). B: Comparison of the cumulative success rate of AGV surgery and trabeculectomy based on criterion B in patients with FUS.
Table 3
Cumulative success rate in different months in trabeculectomy versus Ahmed glaucoma valve (AGV) group.
Survival group 6 months 12 months 24 months 36 months
Criterion A Criterion B Criterion A Criterion B Criterion A Criterion B Criterion A Criterion B
Trabeculectomy 100% (na ¼ 16) 93% (n ¼ 16) 100% (n ¼ 13) 75% (n ¼ 13) 76% (n ¼ 7) 65% (n ¼ 7) 76% (n ¼ 7) 65% (n ¼ 7)
Ahmed glaucoma valve (AGV) 91% (n ¼ 12) 58% (n ¼ 12) 91% (n ¼ 10) 49% (n ¼ 10) 61% (n ¼ 7) 20% (n ¼ 7) 9% (n ¼ 6) 7% (n ¼ 6)
Since our study was a longitudinal study, we had some patients with loss to follow-up during time which is common in these kinds of study.
a Number of patients in each group in the specific time period.
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ously without any surgical intervention. In the trabeculectomy
group, one case needed bleb needling and subconjunctival in-
jection of MMC in weeks 3, 5, and 7 after surgery.
Discussion
In the current study, we found that the complete and cu-
mulative success rates were significantly higher in the trabe-
culectomy group in comparison with the AGV group during
36 months of follow-up. Although the changes in the IOP from
baseline values in different time points between the two
groups were not significant, based on our definition of success
rate, better control of IOP was found in the trabeculectomy
group. According to our findings, it seems that AGV works
well during the first year after the surgery, but the effects
decline with a steep slope over the following years. This
should be considered especially for those patients with
advanced glaucoma and those with poor compliance for using
medications.
Secondary glaucoma is the most troublesome complication
in FUS and can lead to a permanent visual loss. The etiology
of glaucoma in FUS is poorly understood. Huber considered
the main cause of ocular hypertension to be an increase in the
outflow resistance at the site of the trabecular meshwork.29
Chandler and Grant stated that rubeosis of the iris in the
anterior chamber angle induces the development of chronic
secondary glaucoma.30Previous studies reported a prevalence of 6.5%e59% for
secondary glaucoma in FUS.8 This large variation may be
because of different definitions of glaucoma, follow-up time,
and different manifestations of FUS. Arrelanes-Garcia et al.
noticed elevated IOP at some stage of FUS in 30.66% of their
patients, but the diagnosis of glaucoma was made only in
4%.31 In the cohort of Norrsell and Sj€odell, these percentages
were 24% and 11%, respectively.10 Jones and Liesegang, in
the retrospective studies, found the risk of glaucoma devel-
opment 4% and 0.5% per each year of follow-up,
respectively.8,13
As earlier studies showed, usually glaucoma in FUS be-
comes refractory to medical treatment13,17,18; therefore, sur-
gical intervention is needed to control the IOP. Liesegang
reported sufficient IOP control following one surgery (usual
trabeculectomy without MMC) in 12 of the 21 (57%) pa-
tients.13 La Hey and colleagues reported that surgical inter-
vention (mostly trabeculectomies) was able to control IOP in
72% of patients after a mean follow-up of 26 months.19
In a retrospective study conducted by Iverson et al. patients
with uncontrolled glaucoma due to uveitis (only 1 case of FUS
in each group) that had undergone trabeculectomy with anti-
fibrotic therapy or Baerveldt shunt implantation were
enrolled. At the end of the follow-up mean IOP, the number of
anti-glaucoma medications and also complications were
similar between the two groups. But the cumulative proba-
bility of failure after 5 years of follow-up was significantly
greater in trabeculectomy eyes (62%) compared with
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that non-valved shunt surgery is more likely to maintain IOP
control in long-term.32 Kwon and colleagues33 in a recent
retrospective study on patients with uveitis reported that the
rate of success in the trabeculectomy and glaucoma device
implant was not significantly different.
In the present study, we used a valved shunt (AGV), and the
study subjects were all from FUS patients who had a relatively
benign course in comparison to other types of uveitis. These
factors may affect the final results and differences seen in
these studies. Based on criterion A, we found failure in 6
patients of the AGV group. Of them, 3 patients had IOP more
than 21 mmHg, one patient needed one drug more than the
preoperative number of medications, and 2 patients had both
of the above criteria. In the trabeculectomy group, 2 patients
experienced failure due to the higher number of medications
as compared to preoperative ones. Based on criterion B, 4 and
2 cases were added to the previous failure number in the AGV
and the trabeculectomy groups, respectively, due to the IOP
more than 16 mmHg. In both groups, AGV was implanted for
those cases with the diagnosis of failure with satisfactory IOP
control at the end of the follow-up.
In a study on patients with FUS that underwent trabecu-
lectomy with intraoperative applications of MMC (11 patients
with follow-up of 25.09 ± 14.4 months), You et al. reported
the total success of 90.9% at 1 year, 62.3% at 4 years, and the
complete success of 63.6% and 31.8% at 1 and 4 years,
respectively.25 In a retrospective study by Voykov and col-
leagues, the outcome of AGV implantation in FUS patients
with glaucoma was evaluated. They defined two criteria:
6 mmHg  IOP 21 mmHg (success 1), and 6 mmHg  IOP
21 mmHg and at least a 25% reduction from baseline
(success 2). They reported complete success rates of 23.5%
(n ¼ 17) after 1 year and 23% (n ¼ 13) after 3 years and
qualified success rates of 58.3% (n ¼ 17) after 1 and 38.4%
(n ¼ 13) after 3 years for both definitions.34
In general, the main complication of filtration surgery in
FUS is bleb-related failure including encapsulated bleb and
bleb flattening. Both Jones and La Hey et al. recommended the
use of fibrosis-inhibiting drugs (such as 5-fluorouracil or
MMC) in FUS patients to inhibit this process even though its
benefit has yet to be proven in FUS.8,19 We used MMC in all
trabeculectomy surgeries with no reported case of bleb failure.
The level of preoperative ocular inflammation is always a
concern in glaucoma surgeries and is even more prominent in
uveitis patients. Although Fuchs patients are among the low-
grade uveitis, as a routine, we started steroid drops a week
before surgeries. Thus, on the day of the surgery, eyes were at
a quiescent stage. This strategy also made both groups more
uniform in terms of the preoperative level of inflammation.
The non-randomized and retrospective design of this study
as well as a small number of study subjects and the short
duration of follow-up were among the limitations of this study.
However, to the best of our knowledge, this is the first study
which compared the outcome of trabeculectomy and shunt
surgery in FUS patients with secondary glaucoma. We found a
higher success rate and better IOP result with trabeculectomy.The number of postoperative antiglaucoma medications was
also significantly more in the AGV group, and actually, all
patients in this group needed medication. This is not surprising
and is in concordance with most studies about AGV and
different kinds of glaucoma.
Finally, to better understand the surgical outcome of glau-
coma surgery in FUS patients, randomized control trials with a
longer duration of the follow-up period are recommended.
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